Clinical Trial: Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: One Arm, Open Study to Assess Biochemical Markers of Growth Response to Growth Hormone Treatment in Children With Idiopathic Short Stature
Brief Summary: One arm, open, prospective, intervention study to assess biochemical markers of growth response to Growth Hormone treatment in 20 Children, aged 3-9 years old, with idiopathic short stature. All participants will be treated with Growth Hormone during the first year of the study (and then in accordance with the local ethic requirement, to supply drug which is not approved for the indication used in the study, for additional 3 years) and then will be followed up for the next 3 years. The impact of Growth Hormone therapy on clinical laboratory parameters that are indicative of the growth response will be assessed by collecting blood and urine samples during the 4 years study period. The primary endpoints are measurements of height and growth velocity during the year of Growth Hormone treatment, the height at the beginning of puberty and final height. Secondary endpoints are psychological parameters, assessed by questionnaires.
Detailed Summary:
One arm, open prospective intervention study to assess biochemical markers of growth response to Growth Hormone treatment in 20 children, aged 3-9 years old, with idiopathic short stature.
Objectives:
- To determine axiological and biochemical markers for growth response
- To assess the period of time necessary to determine the parameters which will differentiate between responders and non-responders
Inclusion criteria:
- Ages 3 to <9 years
- Short stature with height >2.25 Standard Deviation below the mean
- Prepubertal (Tanner stage I) at commencement of trial
- Peak Growth Hormone above 10ng/ml in at least one provocative test for Growth Hormone secretion
- Signing Informed consent forms
Exclusion criteria:
- Intra Uterine Growth Retardation
- Growth retardation associated with malignancy, severe chronic disease, genetic syndromes and endocrine disorders
- Diabetes
- Treatment with any medical product which may interfere with Growth Hormone effects
Methods:
- All participants will be treated with Growth Hormone during the first year of the study (and then in accordance with the local ethic requirement, to supply drug which
Sponsor: Rabin Medical Center
Current Primary Outcome:
- Height [ Time Frame: every 4 months ]
- Growth velocity [ Time Frame: every 4 months ]
- Height at beginning of puberty [ Time Frame: At the biginning of puberty ]
- Final height [ Time Frame: When acheiving final height ]
Original Primary Outcome:
- Height
- Growth velocity
- Height at beginning of puberty
- Final height
Current Secondary Outcome:
- Psychological parameters [ Time Frame: once a year ]
- HbA1c and IGF-1 [ Time Frame: at baseline. after 3 months and than every 6 months ]
Original Secondary Outcome: Psychological parameters
Information By: Rabin Medical Center
Dates:
Date Received: April 8, 2007
Date Started: April 2006
Date Completion:
Last Updated: January 1, 2013
Last Verified: October 2011